Home > Healthcare > Pharmaceuticals > Finished Drug Form > Lidocaine Hydrochloride Market

Lidocaine Hydrochloride Market Share

Report ID: GMI9709
Published Date: May 2024
Report Format: PDF

Download Free Sample

Lidocaine Hydrochloride Market Share

The competitive landscape of the market is characterized by the presence of several companies striving to maintain their market positions through various strategies. Also, mergers and acquisitions are prevalent, contributing to market consolidation. Continuous research and development efforts, coupled with the rising demand for pain management solutions, further intensify competition, fostering innovation and driving market growth.

Lidocaine Hydrochloride Market Companies

Some of the prominent players operating in the lidocaine hydrochloride industry include:

AdvaCare Pharma
Amneal Pharmaceuticals LLC
AstraZeneca
B. Braun Melsungen AG
Endo Pharmaceuticals Inc.
Fresenius SE & Co. KGaA
F. Hoffmann-La Roche Ltd.
Gensco Pharma
Glenmark Pharmaceuticals
Guanlang Group
Hisamitsu Pharmaceutical Co., Inc.
Mylan N.V.
PAI Pharma.
Pfizer Inc.
Scilex Holding Company
Septodont Healthcare India Pvt. Ltd.
Taro Pharmaceutical Industries Ltd.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Lidocaine hydrochloride industry size was worth USD 752.5 million in 2023 and is projected to expand at 5.5% CAGR from 2024 to 2032, owing to the increasing prevalence of chronic pain management and neurological disorders.

The injectable dosage form segment in the lidocaine hydrochloride industry accounted for USD 354.2 million in revenue in 2023 and is estimated to depict 5.7% CAGR between 2024 and 2032, as they offer rapid onset of action and precise dosage control, making them ideal for various medical procedures requiring local or regional anesthesia.

The dental procedures segment in the lidocaine hydrochloride industry accounted for 30.8% market share in 2023 and is projected grow at significant rate from 2024 to 2032, due to its potent local anesthetic properties.

U.S. lidocaine hydrochloride market recorded USD 274.4 million in revenue in 2023 and is projected to grow at substantial CAGR between 2024 and 2032, owing to the presence of advanced healthcare infrastructure, high prevalence of surgical procedures, and extensive use of lidocaine in various medical specialties.